Tradegate
24.06.26 | 10:07
3,044 Euro
+2,08 % +0,062
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,966 | 3,024 | 13:04 | |
| 2,952 | 3,010 | 26.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | HANSA BIOPHARMA AB: Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for 'What's Hot, What's New' Plenary at ATC 2026 | 1 | Cision News | ||
| 15.06. | Hansa Biopharma AB: Hansa Biopharma appoints Adam Cutler as new Chief Financial Officer | 129 | GlobeNewswire (Europe) | Lund, Sweden, 15 June 2026. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) announced today the appointment of Adam Cutler as Chief Financial Officer (CFO) and a member of the Executive Committee... ► Artikel lesen | |
| HANSA BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 12.06. | HANSA BIOPHARMA AB: Hansa Biopharma invite to Capital Markets Day 2026 in New York | 1 | Cision News | ||
| 10.06. | Hansa Biopharma AB: Hansa Biopharma appoints Fredrik Röök as VP Business Development | 137 | GlobeNewswire (Europe) | Lund, Sweden, 10 June 2026. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that Fredrik Röök has been appointed as VP Business Development effective 17th August. Mr Röök will report... ► Artikel lesen | |
| 02.06. | HANSA BIOPHARMA AB: Hansa Biopharma participating in Jefferies Global Healthcare Conference in New York | 1 | Cision News | ||
| 01.06. | Hansa Biopharma AB: Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) | 161 | GlobeNewswire (Europe) | Lund, Sweden, June 1, 2026. Hansa Biopharma AB (publ), "Hansa" (Nasdaq Stockholm: HNSA), has today on June 1, 2026 held its Annual General Meeting. The Annual General Meeting was held by physical presence... ► Artikel lesen | |
| 29.05. | HANSA BIOPHARMA AB: Hansa Biopharma's CEO Renée Aguiar-Lucander named one of Sweden's Most Influential Business Women of 2026 | 1 | Cision News | ||
| 27.05. | Hansa Biopharma AB: Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation | 555 | PR Newswire | The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submissionIdefirix was generally well tolerated with a safety profile... ► Artikel lesen | |
| 26.05. | Hansa Biopharma trial results to be presented at ATC in June | 2 | Investing.com | ||
| 26.05. | Hansa Biopharma AB: Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 | 511 | PR Newswire | LUND, Sweden, May 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial... ► Artikel lesen | |
| 20.05. | SERB Pharmaceuticals erwirbt von Hansa Biopharma europäische und MENA-Rechte an Idefirix (Imlifidase) für 115 Mio. € | 404 | GlobeNewswire (Deutschland) | BRÜSSEL, May 20, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals ("SERB") und Hansa Biopharma AB ("Hansa") (Nasdaq Stockholm: HNSA) gaben heute bekannt, dass sie eine Vereinbarung getroffen haben, nach... ► Artikel lesen | |
| 19.05. | Hansa Biopharma Signs IDEFIRIX Licensing Deal With SERB | 1 | Contract Pharma | ||
| 19.05. | SERB To Buy Hansa Biopharma's Idefirix Rights In Europe, MENA For EUR 115 Mln | 1 | RTTNews | ||
| 19.05. | SERB Pharmaceuticals to acquire European and MENA rights to Idefirix (imlifidase) from Hansa Biopharma for €115 million | 1.085 | GlobeNewswire (Europe) | BRUSSELS, May 19, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals ("SERB") and Hansa Biopharma AB ("Hansa") (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under which... ► Artikel lesen | |
| 19.05. | HANSA BIOPHARMA AB: Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA | 3 | Cision News | ||
| 18.05. | HANSA BIOPHARMA AB: Hansa Biopharma participating at LSX Nordic Congress | 8 | Cision News | ||
| 12.05. | HANSA BIOPHARMA AB: Hansa Biopharma participating at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq | 1 | Cision News | ||
| 23.04. | Hansa Biopharma GAAP EPS of -SEK1.93, revenue of SEK34.57M | 2 | Seeking Alpha | ||
| 23.04. | Hansa Biopharma AB: Hansa Biopharma Report First Quarter 2026 Financial Results | 347 | GlobeNewswire (Europe) | PDUFA target date set for December 19 by the FDA
Runway significantly extended
Lund, Sweden, 23 April 2026. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim... ► Artikel lesen | |
| 08.04. | HANSA BIOPHARMA AB: Hansa Biopharma to host Q1 2026 interim results conference call | 2 | Cision News |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,85 | -0,13 % | BioNTech-Aktie: Ist das Unternehmen noch zu retten? | Die Geschichte von BioNTech ist eine der größten Erfolgsgeschichten der deutschen Wirtschaft. Aus einem Mainzer Forschungsunternehmen wurde innerhalb weniger Jahre ein globaler Pharmakonzern, dessen... ► Artikel lesen | |
| EVOTEC | 4,906 | +1,41 % | Evotec-Aktie mit -91% - ist das die letzte Chance? | Die Evotec-Aktie hat seit ihrem Allzeithoch rund -91% an Wert verloren und zählt damit zu den größten Verlierern der vergangenen Jahre. Nach dem massiven Abverkauf bewegt sich der Kurs nun in einer... ► Artikel lesen | |
| MODERNA | 57,96 | -1,91 % | Bayer und PORR werden für Produktionsanlage ausgezeichnet | ||
| VALNEVA | 2,265 | -0,04 % | VALNEVA SE: Valneva Announces Successful Outcome of its Annual General Meeting | Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that... ► Artikel lesen | |
| NOVAVAX | 7,750 | -0,77 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| HEIDELBERG PHARMA | 2,650 | +2,32 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma berichtet über die Ergebnisse der ordentlichen Hauptversammlung 2026 | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Hauptversammlung
Heidelberg Pharma berichtet über die Ergebnisse der ordentlichen Hauptversammlung 2026
23.06.2026 / 15:39... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,750 | -2,97 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 554,60 | 0,00 % | Regeneron Pharmaceuticals, Inc.: Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG) | Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target... ► Artikel lesen | |
| OCUGEN | 1,306 | +0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,969 | +0,68 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,220 | +4,27 % | Innovation in der Forschung: Chancen bei Vertex Pharmaceuticals, BioNxt Solutions und BioNTech! | In Sozialen Medien findet man allerlei negative Kommentare und Memes zum Pfizer Konzern. Eine sehr populäre Behauptung lautet, dass der von deutschen Einwanderern in New York gegründete Konzern (Karl... ► Artikel lesen | |
| INFLARX | 1,687 | -0,24 % | InflaRx NV mit Rekordsignal: Das Signal das die meisten Anleger noch nicht kennen - Meine Einschätzung für die neue Börsenwoche | ||
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| VIVORYON THERAPEUTICS | 1,030 | 0,00 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report |
HANSA BIOPHARMA AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,062 (+2,08 %) liegt der Kurs bei 3,044 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HANSA BIOPHARMA AB finden Sie auf Wallstreet Online.